Why is PTEN an important tumor suppressor?

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) was originally cloned as a tumor suppressor for brain tumors. Now it is known as a tumor suppressor for many tumor types. In this review, we ask the simple question: why is PTEN such a common and important tumor suppressor? The most obvious answer is that there are no other family members that can replace PTEN. As a result, several pathways critical for cell transformation are misregulated. The most important of these is the phosphoinositide 3‐kinase (P13K) PI3K‐Akt pathway, which has downstream effects on transcription, proliferation, cell survival, invasiveness, and angiogenesis. In addition, PTEN is linked via several mechanisms to the p53 tumor suppressor. Through p53 and additional mechanisms, loss of PTEN leads to genomic instability. Hence, PTEN is important because its loss misregulates multiple Akt‐dependent and ‐independent pathways critical for the development of cancer. J. Cell. Biochem. 102: 1368–1374, 2007. © 2007 Wiley‐Liss, Inc.

[1]  Paul D Griffiths,et al.  Association of tuberous sclerosis of temporal lobes with autism and atypical autism , 1997, The Lancet.

[2]  H. Hanafusa,et al.  The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[4]  W. Woods,et al.  PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. , 2003, Cancer research.

[5]  A. Ray,et al.  Breast and prostate cancer , 2000, Indian Journal of Clinical Biochemistry.

[6]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[7]  C. Worby,et al.  A PTEN-like Phosphatase with a Novel Substrate Specificity* , 2004, Journal of Biological Chemistry.

[8]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Chan,et al.  Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer , 2004, British Journal of Cancer.

[10]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[11]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[12]  R. Parsons,et al.  PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells , 2005, Cell cycle.

[13]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[14]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[15]  P. Hawkins,et al.  Signalling through Class I PI3Ks in mammalian cells. , 2006, Biochemical Society transactions.

[16]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[17]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Sood,et al.  AUTISM IN TUBEROUS SCLEROSIS , 1991, Indian journal of psychiatry.

[19]  P. Vogt,et al.  Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.

[20]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[21]  C Eng,et al.  Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations , 2005, Journal of Medical Genetics.

[22]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[23]  M. White,et al.  c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.

[24]  P. Devreotes,et al.  Tumor Suppressor PTEN Mediates Sensing of Chemoattractant Gradients , 2002, Cell.

[25]  G. Krystal,et al.  Lipid phosphatases in the immune system. , 2000, Seminars in immunology.

[26]  Hong Wu,et al.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.

[27]  T. Pandita,et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. , 2005, Cancer cell.

[28]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[29]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[30]  E. Hafen,et al.  Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB , 2002, Science.

[31]  Lewis C Cantley,et al.  Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. , 2005, Genes & development.

[32]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[33]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[34]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[35]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[36]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[37]  R. M. Sharrard,et al.  Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. , 2007, Cellular signalling.

[38]  M. Blasco,et al.  Cellular Senescence in Cancer and Aging , 2007, Cell.

[39]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[40]  Arne Gericke,et al.  Regulation of the PTEN phosphatase. , 2006, Gene.

[41]  A. Saltiel,et al.  Lipid phosphatases as drug discovery targets for type 2 diabetes , 2006, Nature Reviews Drug Discovery.

[42]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[43]  T. Kawabe.  G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.

[44]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[45]  Y. Le Marchand-Brustel,et al.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.

[46]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[47]  P. Pandolfi,et al.  NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN , 2007, Cell.